Shenzhen Kexing Biopharm

Shenzhen Kexing Biopharm is a prominent Chinese biopharmaceutical enterprise focused on the development, manufacturing, and commercialization of recombinant protein therapeutics and micro-ecological preparations. The company's flagship products include EPOSINO (erythropoietin), WHITE-C (filgrastim), and SINOGEN (interferon α1b), which are market leaders in China for treating anemia, neutropenia, and viral infections. Kexing Biopharm maintains a high-standard GMP manufacturing base and has established a significant international footprint, exporting to dozens of countries across Southeast Asia, Latin America, and the Middle East. The company is currently transitioning towards a more innovation-driven model by expanding its pipeline into biosimilars and novel monoclonal antibodies.